香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 根據股份獎勵計劃授出股份獎勵 於2025年12月3日，本公司根據首次公開發售後股份獎勵計劃，通過發行新股份（定 義見上市規則第17章）向3名獎勵承授人授出合共1,958,000股獎勵股份，佔於本公告 日期全部已發行股份（不包括庫存股）約0.18%，惟須待獎勵承授人接納後方可作 實。 已授出獎勵的詳情如下： | 授出日期： | 2025年12月3日 | | --- | --- | | 獎勵承授人數量： | 3名 | | 已授出獎勵數目： | 1,958,000份 | | 獎勵股份代價： | 無 | | 於授出日期股份的 | 每股股份5.10港元，按於授出日期聯交所所報之收市價 | | 市價： | 計算 | – 1 – Yidu Tech Inc. 醫渡科技有限公司 ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) (股份代號：2158) 授出股份獎勵 本公告乃根據上市規則第17.06A、17. ...

Core Viewpoint - The company, Yidu Tech (02158), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will spend HKD 1.9953 million to repurchase 392,000 shares [1] - The buyback price per share ranges from HKD 5.07 to HKD 5.10 [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback on December 3, 2025, spending HKD 1.9953 million to repurchase 392,000 shares [1] - The buyback price per share ranged from HKD 5.07 to HKD 5.10 [1]

Core Viewpoint - The company, Yidu Tech (02158.HK), announced a share buyback on December 3, 2023, spending HKD 1.995 million to repurchase 392,000 shares at a price range of HKD 5.07 to 5.10 per share [1] Summary by Category - **Company Actions** - Yidu Tech executed a buyback of 392,000 shares at a total cost of HKD 1.995 million [1] - The repurchase price per share ranged from HKD 5.07 to HKD 5.10 [1]

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年10月31日 | 1,063,856,231 ...

Core Insights - The "2025 AI for Healthcare Hackathon" successfully concluded in Beijing, showcasing a diverse range of innovative teams from top hospitals, renowned universities, and tech companies, emphasizing a shift from traditional tech competitions to a demand-driven, AI-centric healthcare innovation platform [1][8] - The event highlighted the emergence of AI healthcare projects with both cutting-edge technology and clinical application potential, addressing real-world healthcare needs [1][6] Awards and Recognitions - Notable projects included the "Clinical Trial Intelligent Entry and Exit Review Agent," which achieved end-to-end automation in clinical trial participant screening, and various AI assistants targeting specific medical conditions such as hepatitis B and rare diseases [3][6] - The event also recognized projects focused on enhancing healthcare management and service quality, such as the AI health rumor debunking tool and the foreign patient healthcare assistant [3][7] Evaluation and Support - A multidisciplinary panel of experts from academia, industry, and investment participated in the evaluation process, ensuring a comprehensive assessment of both technological innovation and clinical applicability [5][8] - The hackathon benefited from the support of the medical AI development platform provided by Yidu Tech, which offered resources and training to participating teams, significantly lowering the barriers to AI healthcare application development [5][6] Innovation and Future Directions - The awarded projects collectively represent a new generation of AI healthcare agents that are capable of understanding complex intentions, executing multi-step tasks, and collaborating with human experts [8][9] - The event underscored the importance of focusing on high-value niche scenarios and building sustainable service models in the era of "AI + Healthcare" [9]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]

Core Insights - Yidu Technology reported a total revenue of 358 million yuan for the six months ending September 30, 2025, representing a year-on-year growth of 8.7% [1] - The company's adjusted EBITDA doubled compared to the same period last year, reaching approximately 54 million yuan, indicating significant improvements in profitability and operational efficiency [1] Business Segments - The AI for Medical segment generated revenue of 153 million yuan, reflecting a year-on-year increase of 14.6%. The company has provided solutions to 127 top hospitals and 44 regulatory bodies and policymakers in China [2] - The AI for Life Science segment achieved revenue of 138 million yuan, supporting the accelerated approval of several innovative drugs, including a world-first topical gel for infantile hemangioma and a new drug for chronic hepatitis B [2] - The AI for Care segment reported impressive performance with revenue of 66.67 million yuan, up 30.3% year-on-year. The company has maintained its leading position in the "Hui Min Bao" business in core cities, serving as the main operating platform for "Shenzhen Hui Min Bao" for three consecutive years and "Beijing Pu Hui Health Bao" for five years [2] - The company's diabetes digital therapy has expanded from initial pilot areas to additional locations, with over 22 million active trading users on the health management platform by the end of the reporting period [2] Technological Advancements - YiduCore, the company's core algorithm engine, has processed and analyzed over 1.3 billion patient visits and nearly 7 billion authorized medical records, covering more than 10,000 hospitals and creating a comprehensive disease knowledge graph [1]

Core Insights - The founder and chairwoman of Yidu Tech, Gong Rujing, participated in two major Asia-Pacific industry events, discussing the transformative trends in healthcare and sharing the company's innovative practices in enhancing medical accessibility and efficiency through AI technology [1][3] Group 1: Future Trends in Healthcare - Three core trends in the healthcare industry over the next decade were identified: 1. Autonomous AI reshaping diagnostic and treatment models, transitioning healthcare from reactive treatment to predictive prevention, addressing the global shortage of medical resources [1] 2. Trustworthy data establishing a new national health infrastructure, enhancing public health alertness and emergency response capabilities, facilitating leapfrog development in health governance [1] 3. Social value becoming the core investment orientation, with capital increasingly focusing on solutions that ensure accessibility, clinical quality, and economic affordability in healthcare [1] Group 2: AI Applications and Innovations - Yidu Tech is promoting AI-enabled healthcare through various practical directions, including the establishment of a national-level digital health platform that empowers individuals, exemplified by the BruHealth platform in Brunei, which has reached approximately 550,000 users, covering nearly 86% of the population [4] - The introduction of Dr. Avatar, a digital twin of doctors, allows for remote consultations and follow-ups, while the Doctor Copilot integrates patient data to assist in decision-making and patient education, thereby alleviating the pressure on healthcare providers [6] - AI's value extends beyond clinical applications to the entire healthcare industry chain, enhancing research processes and payment systems, thereby improving overall operational efficiency [8] Group 3: Collaborative Efforts and Vision - The vision of a "trustworthy and inclusive" digital health system was widely recognized at the conferences, emphasizing the need for collaboration between public and private sectors to address healthcare resource disparities and efficiency bottlenecks [8] - Yidu Tech aims to deepen cross-border and cross-sector collaborations to realize the vision of making precision medicine accessible to everyone [8]

Core Insights - The company reported a stable total revenue of 358 million yuan for the first half of the 2026 fiscal year, reflecting a year-on-year growth of 8.7% [1] - Significant progress has been made in the "AI + Public Health" layout, with services covering nearly 30 provinces and cities, and 44 healthcare regulatory agencies [1] - The company has established 27 million resident health records, creating a solid public health service network [1] Financial Performance - The quality of earnings has significantly improved, with adjusted EBITDA doubling year-on-year to 54 million yuan, nearing breakeven on the financial statements [1] - The company achieved this financial milestone a year ahead of management expectations [1] - New orders in the big data platform and life sciences solutions segments grew by 19.7% and 61.1% respectively, providing ongoing momentum for future development [1] Strategic Positioning - The company is deeply involved in the construction of the National AI Application Center in the medical field in Beijing, highlighting its important role in national-level medical AI projects [1] - This strategic positioning aligns with the company's large model technology entering the "scale landing" phase, showcasing the integration of technological innovation with public service [1] - The report indicates that the company is effectively combining its technological advantages with public service needs, expanding the social value boundaries of medical AI while achieving commercial value [1]